OMNI Research Group, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Nutrition Research Division, Health Canada, Ottawa, Ontario, Canada.
Am J Clin Nutr. 2021 May 8;113(5):1361-1371. doi: 10.1093/ajcn/nqaa407.
Periconceptional folic acid (FA) supplementation is recommended to prevent the occurrence of neural tube defects. Currently, most over-the-counter FA supplements in Canada and the United States contain 1 mg FA and some women are prescribed 5 mg FA/d. High-dose FA is hypothesized to impair 1-carbon metabolism. We aimed to determine folate and 1-carbon metabolism biomarkers in pregnant women exposed to 1 mg or 5 mg FA.
This was an ancillary study within the Folic Acid Clinical Trial (FACT), a randomized, double-blinded, placebo-controlled, phase III trial designed to assess the efficacy of high-dose FA to prevent preeclampsia.
For FACT, women were randomized at 8-16 gestational weeks to receive daily 4.0 mg FA (high dose) or placebo (low dose) plus their usual supplementation (≤1.1 mg). Women were recruited from 3 Canadian FACT centers and provided nonfasting blood samples at 24-26 gestational weeks for measurement of RBC and serum total folate, serum unmetabolized FA (UMFA), tetrahydrofolate (THF), 5-methylTHF, 5-formylTHF, 5,10-methenylTHF, and MeFox (pyrazino-s-triazine derivative of 4α-hydroxy-5-methylTHF, a 5-methylTHF oxidation product); total vitamins B-12 and B-6; and plasma total homocysteine. Group differences were determined using χ2, Fisher exact, and Wilcoxon rank-sum tests.
Nineteen (38%) women received high-dose FA and 31 (62%) received low-dose FA. The median RBC folate concentration was 2701 (IQR: 2243-3032) nmol/L and did not differ between groups. The high-dose group had higher serum total folate (median: 148.4 nmol/L, IQR: 110.4-181.2; P = 0.007), UMFA (median: 4.6 nmol/L, IQR: 2.5-33.8; P = 0.008), and 5-methylTHF (median: 126.6 nmol/L, IQR: 98.8-158.6; P = 0.03) compared with the low-dose group (median: 122.8 nmol/L, IQR: 99.5-136.0; median: 1.9 nmol/L, IQR: 0.9-4.1; median: 108.6 nmol/L, IQR: 96.4-123.2, respectively). Other biomarkers of 1-carbon metabolism did not differ.
High-dose FA supplementation in early pregnancy increases maternal serum folate but not RBC folate concentrations, suggesting tissue saturation. Higher UMFA concentrations in women receiving high-dose FA supplements suggest that these doses are supraphysiologic but with no evidence of altered 1-carbon metabolism.
建议在受孕前补充叶酸(FA),以预防神经管缺陷的发生。目前,加拿大和美国的大多数非处方 FA 补充剂含有 1 毫克 FA,有些女性每天服用 5 毫克 FA。高剂量 FA 被假设会损害 1 碳代谢。我们旨在确定接触 1 毫克或 5 毫克 FA 的孕妇中的叶酸和 1 碳代谢生物标志物。
这是叶酸临床研究(FACT)的辅助研究,FACT 是一项随机、双盲、安慰剂对照的 III 期试验,旨在评估高剂量 FA 预防子痫前期的疗效。
对于 FACT,女性在妊娠 8-16 周时随机接受每日 4.0 毫克 FA(高剂量)或安慰剂(低剂量)加她们的常规补充剂(≤1.1 毫克)。女性从加拿大 3 个 FACT 中心招募,并在妊娠 24-26 周时提供非禁食血样,以测量 RBC 和血清总叶酸、血清未代谢 FA(UMFA)、四氢叶酸(THF)、5-甲基 THF、5-甲酰基 THF、5,10-亚甲基 THF 和 MeFox(4α-羟基-5-甲基 THF 的吡嗪三嗪衍生物,5-甲基 THF 的氧化产物);总维生素 B-12 和 B-6;和血浆总同型半胱氨酸。使用 χ2、Fisher 精确检验和 Wilcoxon 秩和检验确定组间差异。
19 名(38%)女性接受高剂量 FA,31 名(62%)女性接受低剂量 FA。RBC 叶酸浓度中位数为 2701(IQR:2243-3032)nmol/L,两组间无差异。高剂量组血清总叶酸(中位数:148.4 nmol/L,IQR:110.4-181.2;P=0.007)、UMFA(中位数:4.6 nmol/L,IQR:2.5-33.8;P=0.008)和 5-甲基 THF(中位数:126.6 nmol/L,IQR:98.8-158.6;P=0.03)均高于低剂量组(中位数:122.8 nmol/L,IQR:99.5-136.0;中位数:1.9 nmol/L,IQR:0.9-4.1;中位数:108.6 nmol/L,IQR:96.4-123.2)。其他 1 碳代谢生物标志物无差异。
妊娠早期高剂量 FA 补充剂增加了母体血清叶酸但不增加 RBC 叶酸浓度,表明组织饱和。接受高剂量 FA 补充剂的女性中 UMFA 浓度较高,表明这些剂量是超生理的,但没有证据表明 1 碳代谢发生改变。